MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles
MiMedx Group (MDXG) is awaiting FTC approval for a deal and faces challenges due to Medicare reimbursement changes. CEO Rice noted a 3Q inflection point with improving margins and $40M in surgical revenue. The company also reported positive data on AMNIOFIX grafts and a $25M settlement related to AXIOFILL.



